These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32918610)

  • 1. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
    Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
    Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
    Taichman LS; Van Poznak CH; Inglehart MR
    Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
    Borreani C; Alfieri S; Infante G; Miceli R; Mariani P; Bosisio M; Vernieri C; Bianchi GV; Capri G
    Oncology; 2021; 99(2):84-95. PubMed ID: 32992318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
    Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
    Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
    de Paulo TRS; Winters-Stone KM; Viezel J; Rossi FE; Aro BL; Trindade ACAC; Codogno JS; Freitas Junior IF
    Disabil Rehabil; 2019 Sep; 41(18):2175-2182. PubMed ID: 29644889
    [No Abstract]   [Full Text] [Related]  

  • 6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
    Caperchione CM; Sabiston CM; Stolp S; Bottorff JL; Campbell KL; Eves ND; Ellard SL; Gotay C; Sharp P; Pullen T; Fitzpatrick KM
    BMC Cancer; 2019 Mar; 19(1):272. PubMed ID: 30917793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
    Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
    J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
    Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
    J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors.
    Jung AY; Behrens S; Schmidt M; Thoene K; Obi N; Hüsing A; Benner A; Steindorf K; Chang-Claude J
    Breast Cancer Res; 2019 Nov; 21(1):117. PubMed ID: 31694687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
    de Paulo TRS; Viezel J; Aro BL; Seidinger SC; Trindade ACAC; Christofaro DGD; Freitas IF
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():33-37. PubMed ID: 28700959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
    Saito T; Ono R; Kono S; Asano M; Fukuta A; Tanaka Y; Takao S; Sakai Y
    Breast Cancer Res Treat; 2020 Jul; 182(1):187-193. PubMed ID: 32399742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW; Hudis CA; Pritchard KI; ; ;
    J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
    Nyrop KA; Callahan LF; Cleveland RJ; Arbeeva LL; Hackney BS; Muss HB
    Oncologist; 2017 Oct; 22(10):1238-1249. PubMed ID: 28698390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.